Skip to main content
Midas Edge

TuHURA Biosciences, Inc./NV

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

HURA$1.51-9.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Additional · Accumulated · Total
Preferred Stock · Common Stock · Paid in · Due from · Equity · Stockholders’
Shares · Dollars · Shares · Dollars · Capital · Stockholders · (Deficit) · Equity
Balances at January 1, 2025278,530$278,53042,323,759$42,324$125,397,691$-$(111,124,569)$14,593,976
Contributed capital for warrants exercised from stockholders--1,208,1041,2083,560,907(3,057,904)-504,211
Stock options exercised, cashless148,533148(148)---
Stock compensation expense----1,424,736--1,424,736
Series A Preferred Stock cash dividend(2,089)(2,089)
Net loss------(6,664,371)(6,664,371)
Balances at March 31, 2025278,530$278,53043,680,396$43,680$130,383,186$(3,057,904)$(117,791,029)$9,856,463
Issuance of common shares for warrants exercised----58,5423,057,904-3,116,446
Issuance of common shares, net of issuance costs--3,363,0763,3638,196,116--8,199,479
Issuance of common shares for Kineta merger--2,868,1692,8686,393,149--6,396,017
Stock options exercised, cashless2,3052(2)---
Stock compensation expense----1,407,047--1,407,047
Series A Preferred Stock cash dividend------(2,089)(2,089)
Net loss------(9,523,835)(9,523,835)
Balances at June 30, 2025278,530$278,53049,913,946$49,913$146,438,038$-$(127,316,953)$19,449,528
Additional · Accumulated · Total
Preferred Stock · Common Stock · Paid in · Due from · Equity · Stockholders’
Shares · Dollars · Shares · Dollars · Capital · Stockholders · (Deficit) · Equity
Balances at January 1, 2026278,530$278,53059,336,104$59,336$161,779,364$-$(141,184,902)$20,932,328
Issuance of common shares in RDO, net of issuance costs--4,242,4244,2426,995,758--7,000,000
Stock compensation expense----2,796,240--2,796,240
Series A Preferred Stock cash dividend------(2,089)(2,089)
Net loss------(7,536,598)(7,536,598)
Balances at March 31, 2026278,530$278,53063,578,528$63,578$171,571,362$-$(148,723,589)$23,189,881
Issuance of common shares in ATM, net of issuance costs--104,000104195,722--195,826
Stock compensation expense----2,143,234--2,143,234
Warrant modification associated with revolving credit facility----2,196,906--2,196,906
Series A Preferred Stock cash dividend------(2,089)(2,089)
Net loss------(9,223,298)(9,223,298)
Balances at June 30, 2026278,530$278,53063,682,528$63,682$176,107,224$-$(157,948,976)$18,500,460
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.